Your session is about to expire
← Back to Search
Taladegib for Advanced Cancer
Study Summary
This trial is testing a new drug to see if it's effective and safe for people with cancer who have a specific mutation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't needed strong medication for an autoimmune disease in the last 2 years, except for thyroid issues.I agree not to donate blood during and for 30 days after the study.You have had a serious allergic reaction or severe allergic response to any part of ENV-101.I do not have serious heart problems or my condition is stable and well-managed.I haven't been part of any clinical study or taken experimental drugs in the last 28 days.I haven't had any cancer other than my current type in the last 5 years, except for minor skin cancers or very early-stage cancers that were fully treated.I haven't had major surgery in the last 28 days and don't expect to need one during the study.I am willing to use birth control during the study and for 3 months after.I am not pregnant or nursing.My tumor has a PTCH1 mutation, confirmed by a certified lab test.I don't have lasting side effects from previous treatments, except for anemia, hair loss, skin color changes, nerve damage from platinum drugs, or stable hormone issues.I can take medicine by mouth.I don't have severe nausea, vomiting, malabsorption issues, or significant bowel surgery that would affect medication absorption.I am at least 18 years old, or if under 18, my bone age is mature enough.I haven't taken strong medication that affects liver enzymes in the last 12 days.I do not have an active infection or confirmed HIV, HBV, or HCV at the start of the study.I am not currently receiving any cancer treatments other than what this study provides.I have fluid buildup needing frequent draining but can have a catheter.I agree not to donate sperm/eggs during and for 3 months after the study.I have tried all standard treatments without success, or I have chosen not to undergo standard treatments.
- Group 1: 300 mg ENV-101
- Group 2: 200 mg ENV-101
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are investigators currently enrolling participants in this research?
"Affirmative. According to the information hosted on clinicaltrials.gov, this experiment is actively searching for potential participants and was initially posted on May 24th 2022. 44 individuals need to be enrolled from 18 different medical locations with November 28th being its most recent update."
What has been the Food and Drug Administration's stance on taladegib (ENV-101) thus far?
"Taladegib (ENV-101) has been assigned a safety rating of 2, as this Phase 2 trial has yielded some data on its security but not yet any proof of efficacy."
How many medical sites are administering this clinical trial?
"This medical experiment is presently enrolling patients from 18 different sites across the US, including Tampa, Madison and San Diego. To reduce difficulties associated with travel, it's suggested that participants select a clinic nearest to them."
How many individuals are being monitored as part of this scientific investigation?
"Affirmative. Clinicaltrials.gov documents show that since its announcement on May 24th 2022, this research study has been actively recruiting participants at 18 different sites and is still searching for 44 more volunteers to join the trial."
Share this study with friends
Copy Link
Messenger